[go: up one dir, main page]

CY1114908T1 - Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες - Google Patents

Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες

Info

Publication number
CY1114908T1
CY1114908T1 CY20131101116T CY131101116T CY1114908T1 CY 1114908 T1 CY1114908 T1 CY 1114908T1 CY 20131101116 T CY20131101116 T CY 20131101116T CY 131101116 T CY131101116 T CY 131101116T CY 1114908 T1 CY1114908 T1 CY 1114908T1
Authority
CY
Cyprus
Prior art keywords
alkyl
hydrogen
het
alkylthio
radical
Prior art date
Application number
CY20131101116T
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Jérôme Emile Georges Guillemont
Elisabeth Thérèse Jeanne Pasquier
David Francis Alain Lançois
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35768940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1114908T1 publication Critical patent/CY1114908T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Χρήση μιας ένωσης για την παρασκευή ενός φαρμάκου για τη θεραπευτική αγωγή μιας βακτηριακής μόλυνσης δεδομένου ότι η βακτηριακή μόλυνση είναι διαφορετική από μια Μυκοβακτηριακή μόλυνση, με την εν λόγω ένωση να είναι μια ένωση του Τύπου (Ιa) ή (Ιb), ένα φαρμακευτικώς αποδεκτό άλας προσθήκης οξέων ή βάσεων αυτής, μια τεταρτοταγής αμίνη αυτής, μια στερεοχημικώς ισομερής μορφή αυτής, μια ταυτομερική μορφή αυτής ή μια μορφή N-οξειδίου αυτής, όπου το R1 είναι υδρογόνο, αλο, αλοαλκυλ, κυανο, υδροξυ, Ar, Het, αλκυλ, αλκυλοξυ, αλκυλθειο, αλκυλοξυαλκυλ, αλκυλθειοαλκυλ, Αr-αλκυλ ή δι(Αr)αλκυλ· το p είναι 1, 2 ή 3· το R2 είναι υδρογόνο· αλκυλ· υδροξυ· μερκαπτο· προαιρετικά υποκατεστημένο αλκυλοξυ· αλκυλοξυαλκυλοξυ· αλκυλθειο· μονο ή δι(αλκυλ)αμινο όπου το αλκυλ μπορεί προαιρετικά να είναι υποκατεστημένο Αr· Ηet ή μία ρίζα του Τύπου (II)· το R3 είναι αλκυλ, Αr, Αr-αλκυλ, Ηet ή Ηet-αλκυλ· το q είναι μηδέν, 1, 2, 3 ή 4· το Χ είναι ένας ευθύς δεσμός ή CΗ2· τα R4 και R5 το καθένα ανεξάρτητα είναι υδρογόνο, αλκυλ ή βενζυλ· ή τα R4 και R5 μπορεί να ληφθούν μαζί, συμπεριλαμβάνοντας το Ν στο οποίο είναι προσαρτημένα· το R6 είναι υδρογόνο ή μία ρίζα του Τύπου (III)· το R7 είναι υδρογόνο, αλκυλ, Αr ή Ηet· το R8 είναι υδρογόνο ή αλκυλ· το R9 είναι οξο· ή τα R8 και R9 μαζί σχηματίζουν τη ρίζα - CH=CH-N=.
CY20131101116T 2005-08-03 2013-12-11 Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες CY1114908T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107159 2005-08-03
EP06778081.7A EP1912647B1 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterical agents

Publications (1)

Publication Number Publication Date
CY1114908T1 true CY1114908T1 (el) 2016-12-14

Family

ID=35768940

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101116T CY1114908T1 (el) 2005-08-03 2013-12-11 Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες

Country Status (28)

Country Link
US (1) US8017606B2 (el)
EP (1) EP1912647B1 (el)
JP (1) JP5410753B2 (el)
KR (1) KR101337237B1 (el)
CN (1) CN101277695B (el)
AR (1) AR054889A1 (el)
AU (1) AU2006274879B2 (el)
BR (1) BRPI0614524B8 (el)
CA (1) CA2615901C (el)
CY (1) CY1114908T1 (el)
DK (1) DK1912647T3 (el)
EA (1) EA014832B1 (el)
ES (1) ES2437575T3 (el)
HR (1) HRP20131116T1 (el)
IL (1) IL189141A (el)
JO (1) JO2952B1 (el)
MX (1) MX2008001602A (el)
MY (1) MY148241A (el)
NO (1) NO341247B1 (el)
NZ (1) NZ565283A (el)
PL (1) PL1912647T3 (el)
PT (1) PT1912647E (el)
RS (1) RS53065B (el)
SI (1) SI1912647T1 (el)
TW (1) TWI381839B (el)
UA (1) UA95916C2 (el)
WO (1) WO2007014940A2 (el)
ZA (1) ZA200801108B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512364B2 (ja) 1992-03-02 1996-07-03 共栄電工株式会社 筒状の被加工物の内面研磨方法および装置
UA86952C2 (uk) * 2004-01-23 2009-06-10 Янссен Фармацевтика Н.В. Похідні хіноліну та їх застосування як мікобактеріальних інгібіторів
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
US20110059948A1 (en) * 2008-01-14 2011-03-10 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents
JP5246715B2 (ja) * 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
WO2010144102A1 (en) * 2009-06-09 2010-12-16 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command Pentafluorosulfanyl analogs of mefloquine
US9133167B2 (en) 2012-04-27 2015-09-15 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CN104254528B (zh) 2012-04-27 2017-06-06 詹森药业有限公司 抗菌的喹啉衍生物
JP6250686B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ.ベー. Rorγtのヘテロアリール結合させたキノリニルモジュレータ
ME02794B (me) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9642858B2 (en) 2012-10-30 2017-05-09 University of Pittsburgh—of the Commonwealth System of Higher Education Use of resazurin, or analogs thereof, for antibacterial therapy
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
EP3560920A1 (en) 2013-10-15 2019-10-30 Janssen Pharmaceutica NV Secondary alcohol quinolinyl modulators of ror gamma t
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
ES2770727T3 (es) 2013-10-15 2020-07-02 Janssen Pharmaceutica Nv Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
GB201904796D0 (en) * 2019-04-04 2019-05-22 Univ Sheffield Antimicrobial agent
AR121682A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317491D0 (en) 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
GB9914486D0 (en) * 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
RS52431B (sr) 2002-07-25 2013-02-28 Janssen Pharmaceutica N.V. Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora
US7223776B2 (en) * 2002-10-10 2007-05-29 Morphochem Ag Compounds with anti-bacterial activity
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US7928104B2 (en) * 2003-11-20 2011-04-19 Dominique Jean-Pierre Mabire 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
EP1709012B1 (en) * 2003-12-05 2015-07-29 Janssen Pharmaceutica NV 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose)polymerase inhibitors
UA86952C2 (uk) * 2004-01-23 2009-06-10 Янссен Фармацевтика Н.В. Похідні хіноліну та їх застосування як мікобактеріальних інгібіторів
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
AU2006274879A1 (en) 2007-02-08
TWI381839B (zh) 2013-01-11
HK1124233A1 (en) 2009-07-10
MX2008001602A (es) 2008-02-19
NO341247B1 (no) 2017-09-25
RS53065B (sr) 2014-04-30
EA200800501A1 (ru) 2008-10-30
IL189141A0 (en) 2008-08-07
UA95916C2 (ru) 2011-09-26
CA2615901A1 (en) 2007-02-08
WO2007014940A8 (en) 2007-07-05
PT1912647E (pt) 2013-12-05
IL189141A (en) 2015-10-29
US20080255116A1 (en) 2008-10-16
EP1912647A2 (en) 2008-04-23
AU2006274879B2 (en) 2013-01-10
ZA200801108B (en) 2009-05-27
JO2952B1 (en) 2016-03-15
US8017606B2 (en) 2011-09-13
KR101337237B1 (ko) 2013-12-06
WO2007014940A2 (en) 2007-02-08
KR20080038380A (ko) 2008-05-06
JP2009503024A (ja) 2009-01-29
EA014832B1 (ru) 2011-02-28
WO2007014940A3 (en) 2007-03-29
AR054889A1 (es) 2007-07-25
BRPI0614524A2 (pt) 2011-04-05
BRPI0614524B1 (pt) 2020-05-19
BRPI0614524B8 (pt) 2021-05-25
CA2615901C (en) 2014-06-03
JP5410753B2 (ja) 2014-02-05
PL1912647T3 (pl) 2014-02-28
SI1912647T1 (sl) 2014-01-31
NZ565283A (en) 2011-07-29
TW200744594A (en) 2007-12-16
ES2437575T3 (es) 2014-01-13
EP1912647B1 (en) 2013-09-11
CN101277695A (zh) 2008-10-01
NO20080955L (no) 2008-02-25
CN101277695B (zh) 2011-12-14
DK1912647T3 (da) 2013-12-02
HRP20131116T1 (hr) 2013-12-20
MY148241A (en) 2013-03-29

Similar Documents

Publication Publication Date Title
CY1114908T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1114318T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1112247T1 (el) Παραγωγα κινολινης για τη θεραπευτικη αντιμετωπιση της λανθανουσας φυματιωσης
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MY139243A (en) Prodrugs of piperazine and substituted piperidine antiviral agents.
CY1113535T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1113579T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
AR051989A1 (es) Derivados de quinolina como agentes antibacterianos
NO20080499L (no) Kinolinderivater som antibakterielle midler
CY1113733T1 (el) Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων
CY1112230T1 (el) Αντιβακτηριακα παραγωγα κινολινης
NO20080481L (no) Kinolinderivater som antibakterielle midler
BRPI0515344A (pt) composto, composição farmacêutica, e, usos de uma quantidade eficaz de um composto 3-fosfoindol ou sal, pró-droga, estereoisÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo e de uma quantidade de tratamento eficaz anti-hiv de um composto de 3-fosfoindol ou sal, pró-droga, estereo-isÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
BRPI0414778A (pt) 6-aril-7-halo-imidazo[1,2-a]pirimidinas como agentes anticáncer